ClinicalTrials.Veeva

Menu
L

Life Clinical Trials | Margate, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Upadacitinib
BIIB059
Litifilimab
Tc 99m
BMS-986165
MTX
Ixekizumab
Deucravacitinib
EHP-101
HZN-825

Parent organization

This site is a part of Life Clinical Trials

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 18 total trials

A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial. Participants will be screened within 6 weeks prior to the Bas...

Active, not recruiting
Diffuse Cutaneous Systemic Sclerosis
Sclerosis, Systemic
Drug: Placebo
Drug: HZN-825 QD

Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to...

Active, not recruiting
Vitiligo
Drug: Upadacitinib
Other: NB-UVB (narrow-band ultraviolet B) Phototherapy

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Enrolling
Hidradenitis Suppurativa
Drug: Upadacitinib
Drug: Placebo

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe System...

Enrolling
Systemic Lupus Erythematosus
Drug: Deucravacitinib
Other: Placebo
Locations recently updated

This study will evaluate the safety and efficacy of empasiprubart compared with placebo in adult participants with dermatomyositis (DM).The study dur...

Enrolling
Myositis
Dermatomyositis
Other: Placebo IV
Biological: Empasiprubart IV

This is a parallel group, Phase 2, randomized, double-blind, placebo controlled, 5-arm, international, multicenter, 12-week proof of concept, dose fi...

Enrolling
Rheumatoid Arthritis
Drug: SAR441566
Drug: Placebo

The primary objective of this study is to evaluate the long-term safety and tolerability of litifilimab in participants with active systemic lupus er...

Invitation-only
Systemic Lupus Erythematosus (SLE)
Drug: Litifilimab-matching placebo
Drug: Litifilimab

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Enrolling
Alopecia Areata
Drug: Upadacitinib
Drug: Placebo

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). T...

Enrolling
Lupus Erythematosus, Systemic
Drug: Placebo
Drug: Litifilimab

The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus peglot...

Enrolling
Gout
Drug: Methotrexate
Biological: Pegloticase
Locations recently updated

The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at leas...

Enrolling
Obesity
Psoriatic Arthritis
Drug: Tirzepatide
Drug: Ixekizumab

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how s...

Enrolling
Systemic Lupus Erythematosus
Drug: Upadacitinib
Drug: Placebo

Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how...

Enrolling
Rheumatoid Arthritis
Drug: Adalimumab
Drug: Upadacitinib

Trial sponsors

AbbVie logo
Amgen logo
Biogen logo
Bristol-Myers Squibb (BMS) logo
E
Idorsia Pharmaceuticals logo
Lilly logo
N
Sanofi logo
argenx logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems